1. Home
  2. ICCM vs FGEN Comparison

ICCM vs FGEN Comparison

Compare ICCM & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.71

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Logo FibroGen Inc

FGEN

FibroGen Inc

HOLD

Current Price

$9.71

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
FGEN
Founded
2006
1993
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
35.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ICCM
FGEN
Price
$0.71
$9.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$2.50
$146.50
AVG Volume (30 Days)
372.4K
41.9K
Earning Date
11-19-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
53.38
Revenue
$2,975,000.00
$8,298,000.00
Revenue This Year
$13.67
N/A
Revenue Next Year
$38.55
N/A
P/E Ratio
N/A
$0.18
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$4.85
52 Week High
$1.66
$21.94

Technical Indicators

Market Signals
Indicator
ICCM
FGEN
Relative Strength Index (RSI) 57.45 59.22
Support Level $0.58 $8.50
Resistance Level $0.68 $9.32
Average True Range (ATR) 0.03 0.51
MACD 0.01 0.13
Stochastic Oscillator 91.48 97.24

Price Performance

Historical Comparison
ICCM
FGEN

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Share on Social Networks: